Tumor Protein p53
TP53proteinp53 promotes ferritinophagy-driven iron metabolism during myocardial ischemia and contributes to cardiomyocyte death and plaque instability.
Pathway placement
Cascade stepMyocardial injury (shared endpoint)
Confidencemedium
RationaleMediates ferritinophagy in myocardial injury; implicated in plaque rupture and cardiomyocyte apoptosis.
Also acts inCap degradation / rupture, Vascular inflammation
Druggability
DruggableYes
Known drugs / candidates9
Small-molecule tractableYes
Antibody tractableNo
EnsemblENSG00000141510
Type I vs non-Type I discrimination
ScoresNon-Type-I-associated
R — rupture / Type-I—
C — non-Type-I50
A — assay feasibility72
E — evidence strength40
T1DI (composite)9
Specificity differential (R−C)-35
Non-Type-I axis panel
Does this marker also move in each non-Type-I setting? mag 0–3; higher means less Type-I-specific. n/a = no evidence retrieved, which is not the same as no change.
2sepsis / systemic inflammationn/a
2anemia / acute blood lossn/a
2hypovolemia / dehydrationn/a
2tachyarrhythmian/a
2hypoxemia / respiratory failuren/a
2hypertensive emergencyn/a
2high-demand / peri-operative stressn/a
3sudden cardiac deathmag 1
4aPCI-related periproceduraln/a
4bstent thrombosisn/a
4cin-stent restenosismag 2
5CABG-relatedn/a
Coverage: 2/12 axes with evidence
Tier: deep-scored (abstract-extracted) · 23 supporting references. See the discrimination table for all markers.
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)
Literature evidence(2)
- Multi-omics approach to personalised treatment: insights into thrombus-derived exosome regulation in cardiomyocyte ferritinophagy.Frontiers in immunology · 2025 · PMID 40948766 · doi
- Dynamic Changes in Plasma Urotensin II and Its Correlation With Plaque Stability.Journal of cardiovascular pharmacology · 2021 · PMID 34173803 · doi